MRRS adds "Global Hematological Cancers Market to 2022 – Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma.

Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development.

Table of Contents
3 Key Marketed Products 30
3.1 Overview 30
3.2 Rituxan/Mabthera (rituximab) - Roche 31
3.3 Gleevec/Glivec (Imatinib) - Novartis 33
3.4 Revlimid (lenalidomide) - Celgene 35
3.5 Velcade (bortezomib) - Millennium/Takeda/Johnson & Johnson 37
3.6 Sprycel (dasatinib) - Bristol-Myers Squibb/Otsuka Pharmaceutical 38
3.7 Tasigna (nilotinib) - Novartis 39
3.8 Pomalyst (pomalidomide) - Celgene 41
3.9 Vidaza (azacitidine) - Celgene 42
3.10 Kyprolis (carfilzomib) - Onyx/Amgen 43
3.11 Adcetris (brentuximab vedotin) - Seattle Genetics/Millennium 45
3.12 Imbruvica (ibrutinib) - AbbVie/Johnson & Johnson 46
3.13 Conclusion 48
4 Pipeline Landscape Assessment 49
4.1 Overview 49
4.2 Pipeline Development Landscape 49
4.3 Molecular Targets in the Pipeline 52
4.4 Clinical Trials 54
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 54
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 58
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 61
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 64
4.4.5 Conclusion 67
4.5 Multi-scenario Market Forecast to 2023 68
4.5.1 Overall Market Size 68
4.6 Generic Penetration 70
5 Revenue Forecast by Molecular Target 72......

List of Tables and Figures 
Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016 11
Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016 23
Table 3: Hematological Cancers Therapeutics Market, Global, Multiple Myeloma, Prognostic Factors, 2016 25
Table 4: Hematological Cancers Therapeutics Market, Global, Commonly Used Chemo-Regimens, 2016 28
Table 5: Hematological Cancers Therapeutics Market, Global, Approved Indications for Rituxan, 2016 32
Table 6: Hematological Cancers Therapeutics Market, Global, Approved Indications for Gleevec, 2016 34
Table 7: Hematological Cancers Therapeutics Market, Global, Approved Indications for Revlimid, 2016 35
Table 8: Hematological Cancers Therapeutics Market, Global, Approved Indications for Velcade, 2016 37
Table 9: Hematological Cancers Therapeutics Market, Global, Approved Indications for Sprycel, 2016 38
Table 10: Hematological Cancers Therapeutics Market, Global, Approved Indications for Tasigna, 2016 40
Table 11: Hematological Cancers Therapeutics Market, Global, Approved Indications for Pomalyst, 2016 41
Table 12: Hematological Cancers Therapeutics Market, Global, Approved Indications for Vidaza, 2016 42
Table 13: Hematological Cancers Therapeutics Market, Global, Approved Indications for Kyprolis, 2016 44
Table 14: Hematological Cancers Therapeutics Market, Global, Approved Indications for Adcetris, 2016 45.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-hematological-cancers-market-to-2022-commercially-successful-targeted-therapies-and-large-innovative-pipeline-to-drive-market

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/